• First participant enrolled in randomized control trial designed to demonstrate safety and efficacy of Insulet's fully closed-loop automated insulin delivery system versus standard therapy
  • Unique algorithm automatically adjusts insulin delivery, eliminating mealtime interaction and redefining the healthcare provider experience

Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, has enrolled the first participant in a pivotal study for its fully closed-loop (FCL)A automated insulin delivery (AID) system for type 2 diabetes (T2D). FCL for T2D is a breakthrough innovation intended to further improve glycemic outcomes with less burden for users across diverse care settings. That includes eliminating user interactions for bolusing and mealtime announcements for people with T2D as well as settings to start and onboard.